BTIG assumed coverage of Verastem (VSTM) with a Buy rating and $19 price target The firm views Verastem as an “undervalued oncology story.” The shares are trading at an attractive entry point supported by its two main pipeline programs, the analyst tells investors in a research note. BTIG believes Verastem has commercial launch momentum in low-grade serous ovarian cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem Earnings Call: Early Momentum, Long Runway Risks
- Verastem: Differentiated Next‑Generation KRAS G12D Inhibitor VS‑7375 Underpins Buy Rating on Compelling Early Clinical Data
- Verastem price target raised to $18 from $16 at Alliance Global
- Verastem: Strong Commercial Uptake and Expanding RAS/MAPK Oncology Pipeline Underpin Buy Rating and $18 Target
- Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks